Revium Rx
reviumrx.comWhat Do They Do?
Develops nanoparticle-based medicines for infectious diseases, solid tumors and vaccines, using lipid particles to deliver treatments.
10-K for FY2025, filed Mar 31, 2026We are a pre-clinical stage biopharmaceutical company focused on the development and eventual commercialization of innovative and…View ↗
Our programs are focused on infectious diseases, including antibiotic-resistant infections, solid tumors and a novel approach to…View ↗
We are developing a portfolio of lipid based and Nano-Liposomal Particle NLP-based pharmaceutical candidates and plan to complete the…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$748KView ↗
- ▼ −28% (Loss)
- vs −$1M in Q2 FY2025
-
Jun 1, 2026
The company appointed a new chief financial officer
Igor Bluvstein replaced Arie Gordashnikov, who resigned.
Sources
8-K, filed Jun 1, 2026
Resignation of Mr. Arie Gordashnikov from his position as Chief Financial OfficerView ↗
-
Apr 20, 2026
The company named its interim chief executive officer permanent
The board appointed Amir Avraham permanent CEO, effective February 1, 2026.
Sources
8-K, filed Apr 20, 2026
On April 14, 2026, the Board of Directors of Revium Rx (“we,” “us,” “our,” “Revium” or the “company”) appointed Mr. Amir Avraham, who has…View ↗
Who Do They Compete With?
Competes with Spero Therapeutics, Entasis Therapeutics, Acurx Pharmaceuticals, AGILeBiotics, Geom Therapeutics, LegoChem Biosciences, Innoviva, VenatoRx Pharmaceuticals, Forge Therapeutics, Pherecydes Pharma, BiomX, ContraFect, Polyphor, Matinas BioPharma, and Encapsula NanoSciences
10-K for FY2025, filed Mar 31, 2026Among our direct competitors are companies advancing new chemical entities (NCEs) that exhibit novel mechanisms of action against resistant…View ↗
Loading...
